ALS damages the motor neurons in the brain and spinal cord, leading to a gradual weakening of the muscles. The disease first makes it harder to speak, move and swallow, and it eventually weakens the muscles needed for breathing.
Most people with ALS die within a few years of their diagnosis.
Your donation helps develop a new kind of treatment for people with ALS
A research group at the University of Helsinki is developing a neurorestorative drug candidate that could slow the progression of the disease and improve patients’ quality of life. The group, led by Associate Professor Merja Voutilainen, has already achieved encouraging results in animal models of ALS. In these studies, the treatment delayed the onset of symptoms, improved motor function, protected nerve cells in the spinal cord and reduced inflammation and cellular stress. These results offer real hope that the progression of ALS could one day be slowed and possibly even stopped.
Donations will fund the crucial follow-up studies that must be completed before the drug can be given to patients. These studies will confirm the treatment’s efficacy and safety, determine the right dose and investigate its mechanism of action. Every donation moves this work forward.
Your donation supports work that could give people with ALS more time with their loved ones, a better quality of life and, above all, the chance of an entirely new kind of treatment for the disease.
“My spouse died of ALS less than two years after being diagnosed. We saw first-hand how the disease gradually took away their ability to speak, eat and move, until we had to say goodbye,” says Satu Puustinen.
“There is currently no cure for ALS, but the work of Merja Voutilainen’s research group gives me hope that things could be different for other families in the future. Every donation brings a new treatment one step closer to patients.